Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone

Journal of Thoracic Oncology

Volumn 2, Issue 1, 2007, Pages 73-78

  Yokoi, Kohei ^a,b   Matsuguma, Haruhisa ^a   Nakahara, Rie ^a   Kondo, Tetsuro ^a   Kamiyama, Yukari ^a   Mori, Kiyoshi ^a   Miyazawa, Naoto ^a  

^a TOCHIGI CANCER CENTER   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Multimodality treatment; Thymoma

Indexed keywords

CISPLATIN; DOXORUBICIN; METHYLPREDNISOLONE; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; FEMALE; HUMAN; INFECTION; LEUKOPENIA; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; SUPERIOR CAVA VEIN; SURVIVAL RATE; SURVIVAL TIME; THYMOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; SURVIVAL RATE; THYMOMA; THYMUS NEOPLASMS;

EID: 34249734932     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31802bafc8     Document Type: Article

References (22)

1. Nakahara K, Ohno K, Hashimoto J, et al. Thymoma: results with complete resection and adjuvant postoperative irradiation in 141 consecutive patients. J Thorac Cardiovasc Surg 1988;95:1041-1047.
2. Blumberg D, Port JL, Weksler B, et al. Thymoma: a multivariate analysis of factors predicting survival. Ann Thorac Surg 1995; 60: 908-914.
3. Regnard JF, Magdeleinat P, Dromer C, et al. Prognostic factors and long-term results after thymoma resection: a series of 307 patients. J Thorac Cardiovasc Surg 1996;112:376-384.
4. Ichinose Y, Ohta M, Yano T, Yokoyama H, Asoh H, Hata K. Treatment of invasive thymoma with pleural dissemination. J Surg Oncol 1993;54:180-183.
5. Okumura M, Miyoshi S, Takeuchi Y, et al. Results of surgical treatment of thymomas with special reference to the involved organs. J Thorac Cardiovasc Surg 1999;117:605-613.
6. Fornasiero A, Daniele O, Ghiotto C, Clerico M, Sahmoud T, van Zandwijk N. Chemotherapy for invasive thymoma. A 13-year experience. Cancer 1991;68:30-33.
7. Giaccone G, Ardizzoni A, Kirkpatrick A, et al. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1996;14:814-820.
8. Loehrer PJ, Sr, Chen M, Kim KM, et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol 1997;15:3093-3099.
9. Highley MS, Underhill CR, Parnis FX, et al. Treatment of invasive thymoma with single-agent ifosfamide. J Clin Oncol 1999;17:2737-2744.
10. Rea F, Sartori F, Loy M, et al. Chemotherapy and operation for invasive thymoma. J Thorac Cardiovasc Surg 1993;106:543-549.
11. Venuta F, Rendina EA, Pescarmona EO, et al. Multimodality treatment of thymoma: a prospective study. Ann Thorac Surg 1997;64:1585-1592.
12. Shin DM, Walsh GL, Komaki R, et al. A multidisciplinary approach to therapy for unresectable malignant thymoma. Ann Intern Med 1998;129:100-104.
13. Rea F, Marulli G, Girardi R, et al. Long-term survival and prognostic factors in thymic epithelial tumours. Eur J Cardiothorac Surg 2004;26:412-418.
14. Venuta F, Rendina EA, Longo F, et al. Long-term outcome after multimodality treatment for stage III thymic tumors. Ann Thorac Surg 2003;76:1866-1872.
15. Kim ES, Putnam JB, Komaki R, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 2004;44:369-379.
16. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981;48:2485-2492.
17. Rosai J, Sobin LH. Histological Typing of Tumours of the Thymus. International Histological Classification of Tumours, 2nd ed. New York: Springer, 1999.
18. Yokoi K, Miyazawa N, Kano Y, et al. Tumor lysis syndrome in invasive thymoma with peripheral blood T-cell lymphocytosis. Am J Clin Oncol 1997;20:86-89.
19. Yokoi K, Miyazawa N, Mori K, et al. Invasive thymoma with intracaval growth into the right atrium. Ann Thorac Surg 1992;53:507-509.
20. Hu E, Levine J. Chemotherapy of malignant thymoma. Case report and review of the literature. Cancer 1986;57:1101-1104.
21. Ruffini E, Mancuso M, Oliaro A, et al. Recurrence of thymoma: analysis of clinicopathologic features, treatment, and outcome. J Thorac Cardiovasc Surg 1997;113:55-63.
22. Regnard JF, Zinzindohoue F, Magdeleinat P, Guibert L, Spaggiari L, Levasseur P. Results of re-resection for recurrent thymomas. Ann Thorac Surg 1997;64:1593-1598.